First person profile: Ruth M. O’Regan, MD

This news section offers Cancer readers timely information on events, public policy analysis, topical issues, and personalities. This issue includes a profile of Dr Ruth M. O’Regan, who promotes work‐life balance, collaboration, equal access to education, and care for all. Also, adding two cycles of the immunotherapy blinatumomab to chemotherapy for children with newly diagnosed standard‐risk B‐cell ALL improved outcomes significantly, and high response rates were seen with novel CAR T‐cell therapy for adults with advanced B‐cell ALL.